Production (Stage)
Sensei Biotherapeutics, Inc.
SNSE
$0.295
-$0.014-4.53%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 12.07M | 12.34M | 13.95M | 14.68M | 16.87M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.51M | 30.96M | 32.68M | 32.60M | 34.99M |
Operating Income | -29.51M | -30.96M | -32.68M | -32.60M | -34.99M |
Income Before Tax | -29.03M | -30.16M | -29.80M | -29.67M | -31.92M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -29.03 | -30.16 | -29.80 | -29.67 | -31.92 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -29.03M | -30.16M | -29.80M | -29.67M | -31.92M |
EBIT | -29.51M | -30.96M | -32.68M | -32.60M | -34.99M |
EBITDA | -28.48M | -29.64M | -31.36M | -31.28M | -33.66M |
EPS Basic | -1.15 | -1.20 | -1.19 | -1.18 | -1.20 |
Normalized Basic EPS | -0.70 | -0.72 | -0.75 | -0.75 | -0.76 |
EPS Diluted | -1.15 | -1.20 | -1.19 | -1.18 | -1.20 |
Normalized Diluted EPS | -0.70 | -0.72 | -0.75 | -0.75 | -0.76 |
Average Basic Shares Outstanding | 100.61M | 100.47M | 100.28M | 100.65M | 106.05M |
Average Diluted Shares Outstanding | 100.61M | 100.47M | 100.28M | 100.65M | 106.05M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |